Cupid Limited has informed the Exchange regarding a press release dated August 08, 2025, titled "IVD Test Kits Business".
CUPID · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cupid Limited announced a significant scaling of its In-Vitro Diagnostic (IVD) test kits business, highlighting 15 rapid test kits in production (including HIV, Syphilis, Pregnancy, and Hepatitis B) with 3 new kits in development. CE certification for 4 key products is expected in 2025, and WHO prequalification for Malaria test kits is targeted by mid-2026. Manufacturing capacity is set to quadruple from 1 lakh kits/day to 4 lakh kits/day by end-2026 through phased automation, with new machines being installed in Q2 and Q3 FY26. The company is already supplying 120+ ESIC hospitals via the Government e-Marketplace and has begun operations in 9 countries including Tanzania, Ghana, Bangladesh, and the Philippines. Management positions IVD as a high-impact, high-margin growth vertical alongside its existing condom and FMCG businesses.
Positive strategic update for shareholders — the IVD vertical is being positioned as a future growth engine, with potential to meaningfully expand margins and revenue mix. Capacity quadrupling and global certification pipeline could support earnings growth from FY26 onwards, though execution and regulatory timelines remain key risks.